FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes
__
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Result of AGM
9
April 2026
Results of Annual General Meeting held on 9 April 2026
AstraZeneca PLC announced the results of the voting at its Annual
General Meeting (AGM) today. As proposed in the Notice of AGM, all
Resolutions were decided by poll vote. Resolutions 10 - 13 were
passed as special resolutions; all other resolutions were passed as
ordinary resolutions.
|
|
Resolution
|
Votes for
|
% of votes cast
|
Votes against
|
% of votes cast
|
Votes cast in total
|
Total votes cast as a % of issued share capital
|
Votes withheld
|
|
1
|
To receive the Company's Accounts, the Reports of the Directors and
Auditor and the Strategic Report for the year ended 31 December
2025
|
1,198,663,815
|
99.99%
|
166,701
|
0.01%
|
1,198,830,516
|
77.29%
|
2,309,793
|
|
2
|
To confirm the 2025 interim dividends
|
1,199,596,253
|
99.91%
|
1,054,621
|
0.09%
|
1,200,650,874
|
77.41%
|
489,438
|
|
3
|
To appoint KPMG LLP as Auditor
|
1,200,331,533
|
99.98%
|
203,239
|
0.02%
|
1,200,534,772
|
77.40%
|
605,649
|
|
4
|
To authorise the Directors to agree the remuneration of the
Auditor
|
1,200,231,237
|
99.98%
|
277,426
|
0.02%
|
1,200,508,663
|
77.40%
|
631,646
|
|
5a
|
To re-elect Michel Demaré as a Director
|
1,181,183,631
|
98.39%
|
19,312,258
|
1.61%
|
1,200,495,889
|
77.40%
|
644,420
|
|
5b
|
To re-elect Pascal Soriot as a Director
|
1,188,466,505
|
99.00%
|
12,056,196
|
1.00%
|
1,200,522,701
|
77.40%
|
617,611
|
|
5c
|
To re-elect Aradhana Sarin as a Director
|
1,191,427,943
|
99.30%
|
8,391,362
|
0.70%
|
1,199,819,305
|
77.36%
|
1,321,004
|
|
5d
|
To re-elect Philip Broadley as a Director
|
1,171,470,116
|
97.59%
|
28,983,447
|
2.41%
|
1,200,453,563
|
77.40%
|
686,746
|
|
5e
|
To re-elect Euan Ashley as a Director
|
1,197,441,098
|
99.75%
|
3,022,489
|
0.25%
|
1,200,463,587
|
77.40%
|
676,722
|
|
5f
|
To re-elect Birgit Conix as a Director
|
1,200,028,460
|
99.96%
|
428,931
|
0.04%
|
1,200,457,391
|
77.40%
|
683,030
|
|
5g
|
To re-elect Rene Haas as a Director
|
1,176,085,879
|
97.97%
|
24,361,879
|
2.03%
|
1,200,447,758
|
77.40%
|
692,663
|
|
5h
|
To re-elect Karen Knudsen as a Director
|
1,200,091,469
|
99.97%
|
370,843
|
0.03%
|
1,200,462,312
|
77.40%
|
678,109
|
|
5i
|
To re-elect Diana Layfield as a Director
|
1,199,711,377
|
99.94%
|
755,622
|
0.06%
|
1,200,466,999
|
77.40%
|
673,422
|
|
5j
|
To re-elect Anna Manz as a Director
|
1,199,171,542
|
99.89%
|
1,310,287
|
0.11%
|
1,200,481,829
|
77.40%
|
658,592
|
|
5k
|
To re-elect Sheri McCoy as a Director
|
1,181,129,650
|
98.39%
|
19,334,808
|
1.61%
|
1,200,464,458
|
77.40%
|
675,963
|
|
5l
|
To re-elect Tony Mok as a Director
|
1,197,756,109
|
99.77%
|
2,702,422
|
0.23%
|
1,200,458,531
|
77.40%
|
681,890
|
|
5m
|
To re-elect Marcus Wallenberg as a Director
|
993,713,162
|
83.80%
|
192,121,282
|
16.20%
|
1,185,834,444
|
76.46%
|
15,305,980
|
|
6
|
To approve the annual statement of the Chair of the Remuneration
Committee and the Annual Report on Remuneration for the year ended
31 December 2025
|
1,161,885,452
|
96.78%
|
38,608,771
|
3.22%
|
1,200,494,223
|
77.40%
|
646,086
|
|
7
|
To renew the authorisation to grant awards under the French
Appendix 3 of the AstraZeneca Performance Share Plan
2020
|
1,186,833,063
|
98.89%
|
13,376,194
|
1.11%
|
1,200,209,257
|
77.38%
|
930,948
|
|
8
|
To authorise limited political donations
|
1,176,818,096
|
98.50%
|
17,954,803
|
1.50%
|
1,194,772,899
|
77.03%
|
6,367,525
|
|
9
|
To authorise the Directors to allot shares
|
1,115,450,202
|
92.92%
|
84,989,076
|
7.08%
|
1,200,439,278
|
77.40%
|
701,146
|
|
10
|
To authorise the Directors to disapply pre-emption
rights
|
1,113,184,536
|
92.75%
|
87,024,695
|
7.25%
|
1,200,209,231
|
77.38%
|
930,073
|
|
11
|
To authorise the Directors to further disapply pre-emption rights
for acquisitions and specified capital investments
|
1,053,612,673
|
87.78%
|
146,670,037
|
12.22%
|
1,200,282,710
|
77.39%
|
856,594
|
|
12
|
To authorise the Company to purchase its own shares
|
1,197,748,658
|
99.81%
|
2,335,330
|
0.19%
|
1,200,083,988
|
77.38%
|
1,056,436
|
|
13
|
To reduce the notice period for general meetings
|
1,108,104,727
|
92.31%
|
92,307,790
|
7.69%
|
1,200,412,517
|
77.40%
|
727,904
|
Nazneen Rahman retired from the Board at the conclusion of the
AGM. For
the purposes of section 430(2B) of the Companies Act 2006, she will
receive her pro-rata entitlement to non-executive director fees for
the month of April 2026. No other remuneration payment or payment
for loss of office will be made.
A copy of the resolutions passed at the AGM (other than resolutions
concerning ordinary business) has been submitted to the National
Storage Mechanism for publication, and will shortly be available
for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Issued capital
As at 7 April 2026, the number of issued shares of the Company was
1,550,988,781 ordinary shares, which was the total number of shares
entitling the holders to attend and vote for or against all of the
resolutions at the AGM. In accordance with the Company's Articles
of Association, on a poll every member present in person or by
proxy has one vote for every share held.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 09 April 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|